Ikarian Capital’s Genmab GMAB Stock Holding History

Ikarian Capital’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-175,000	Closed	-$53M	–	197
2025 Q3	$53M	Buy	+175,000	New	+$4.26M	5.35%	3

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ikarian Capital's GMAB Position: Q4 2025 in Review

Ikarian Capital sold out of Genmab (GMAB) in Q4 2025, closing a stake of 175,000 shares — an estimated $53M sold.

Ikarian Capital first reported a position in GMAB in Q3 2025 and held it in 1 quarter. The position peaked at $53M in Q3 2025. 292 funds tracked by Wall St. Rank hold GMAB as of Q4 2025.

Ikarian Capital reported no remaining Genmab position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 175,000 Genmab shares in Q4 2025, an estimated $53M.
Ikarian Capital first reported a position in Genmab in Q3 2025 and held it in 1 quarter.
Ikarian Capital's Genmab position peaked at $53M in Q3 2025.
292 funds tracked by Wall St. Rank held Genmab as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.